Evidence map›Paper›PMID 33420395›Full record

ArticleBone marrow transplantation2021

Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.

Omer Jamy, Alice Chen, Kevin Battles, Liton Francisco, Donna Salzman, Susan Bal, Antonio Di Stasi, Luciano Costa, Ravi Bhatia, Smita Bhatia

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Unequal paths to care: a scoping review of access and cancer outcomes in Alabama.Journal of cancer survivorship : research and practice · 2026
    Review
  2. Review
  3. Article
  4. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Omer JamyDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. omerjamy@gmail.com.ORCID http://orcid.org/0000-0003-2411-4742
Alice ChenInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin BattlesInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Liton FranciscoInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.
Donna SalzmanDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Susan BalDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Antonio Di StasiDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Luciano CostaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-5362-2469
Ravi BhatiaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mortality is highest in the first year following an allogeneic hematopoietic stem cell transplant. With recent advancements, we have expanded the pool of patients to whom we are able to offer transplant as a treatment option. In this context, we analyzed socioeconomic, patient, disease and transplant-related variables that predicted for 1-year all-cause, relapse-related (RRM) and non-relapse related mortality (NRM) in 304 patients at the University of Alabama at Birmingham. The 1-year overall survival, RRM and NRM rates were 60.5%, 13.5% and 22.7% respectively. A KPS score < 80, pre-transplant infection and hypertension and non-complete remission disease status adversely effected all-cause mortality. For NRM, increasing age, pre-transplant infection and diabetes, and poor access to care were associated with higher mortality whereas haploidentical donor type was associated with improved survival. For RRM, a KPS score <80, high/very high disease risk index and the presence of comorbidities were risk factors for higher mortality. Poor access to care, in addition to individual comorbidities, performance status and high-risk disease characteristics, is associated with adverse outcomes following transplant. We propose the incorporation of socioeconomic variables with patient, disease, and transplant-related variables to predict 1-year NRM.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningBone MarrowHealth Services AccessibilityHumansRetrospective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.